139 related articles for article (PubMed ID: 34875558)
1. Real-world effectiveness of antipsychotic treatments in 1011 acutely hospitalized patients with schizophrenia: A one-year follow-up study.
Hatta K; Katayama S; Ishizuka T; Sudo Y; Nakamura M; Hasegawa H; Imai A; Morikawa F; Shimada T; Misawa F; Ozaki S; Fujita K; Watanabe H; Nakamura H; Sugiyama N;
Asian J Psychiatr; 2022 Jan; 67():102917. PubMed ID: 34875558
[TBL] [Abstract][Full Text] [Related]
2. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia.
Tiihonen J; Mittendorfer-Rutz E; Majak M; Mehtälä J; Hoti F; Jedenius E; Enkusson D; Leval A; Sermon J; Tanskanen A; Taipale H
JAMA Psychiatry; 2017 Jul; 74(7):686-693. PubMed ID: 28593216
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
Nielsen J; Jensen SO; Friis RB; Valentin JB; Correll CU
Schizophr Bull; 2015 May; 41(3):627-36. PubMed ID: 25180312
[TBL] [Abstract][Full Text] [Related]
4. Long-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia.
Fang SC; Huang CY; Shao YJ
J Clin Psychiatry; 2022 Jun; 83(4):. PubMed ID: 35649156
[No Abstract] [Full Text] [Related]
5. Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics.
Lin CH; Chen FC; Chan HY; Hsu CC
Int J Neuropsychopharmacol; 2019 Sep; 22(9):541-547. PubMed ID: 31260538
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Long-Acting Injectable Versus Oral Antipsychotics in Patients With Schizophrenia Using the Prevalent New User Design and Subgroup Analyses.
Okada Y; Inada K; Akazawa M
J Clin Psychopharmacol; 2024 May-Jun 01; 44(3):263-271. PubMed ID: 38684048
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
[TBL] [Abstract][Full Text] [Related]
8. The effect of long-acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: A systematic review and meta-analysis.
Okoli CTC; Kappi A; Wang T; Makowski A; Cooley AT
Int J Ment Health Nurs; 2022 Jun; 31(3):469-535. PubMed ID: 34931437
[TBL] [Abstract][Full Text] [Related]
9. Schizophrenia Patients Discharged on Clozapine Plus Long-Acting Injectable Antipsychotics From a Public Psychiatric Hospital in Taiwan, 2006-2021.
Lin TC; Lin CH
Int J Neuropsychopharmacol; 2023 Nov; 26(11):808-816. PubMed ID: 37616565
[TBL] [Abstract][Full Text] [Related]
10. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
[TBL] [Abstract][Full Text] [Related]
11. Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics.
Mahlich J; Olbrich K; Wilk A; Wimmer A; Wolff-Menzler C
Clin Drug Investig; 2021 Jan; 41(1):99-113. PubMed ID: 33331979
[TBL] [Abstract][Full Text] [Related]
12. A Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics on Time to Rehospitalization Within 1 Year of Discharge in Elderly Patients With Schizophrenia.
Lin CH; Chen FC; Chan HY; Hsu CC
Am J Geriatr Psychiatry; 2020 Jan; 28(1):23-30. PubMed ID: 31481273
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic treatment and risk of discontinuation and hospitalization in first-episode schizophrenia: a nationwide population-based study.
Joo SW; Kim H; Jo YT; Choi YJ; Ahn S; Lee J
Psychol Med; 2023 Jan; 53(1):181-188. PubMed ID: 33855950
[TBL] [Abstract][Full Text] [Related]
14. 20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia.
Tiihonen J; Tanskanen A; Taipale H
Am J Psychiatry; 2018 Aug; 175(8):765-773. PubMed ID: 29621900
[TBL] [Abstract][Full Text] [Related]
15. Risk of discontinuation of antipsychotic long-acting injections vs. oral antipsychotics in real-life prescribing practice: a community-based study.
Verdoux H; Pambrun E; Tournier M; Bezin J; Pariente A
Acta Psychiatr Scand; 2017 May; 135(5):429-438. PubMed ID: 28332704
[TBL] [Abstract][Full Text] [Related]
16. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.
Tiihonen J; Taipale H; Mehtälä J; Vattulainen P; Correll CU; Tanskanen A
JAMA Psychiatry; 2019 May; 76(5):499-507. PubMed ID: 30785608
[TBL] [Abstract][Full Text] [Related]
17. Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia.
Lafeuille MH; Dean J; Carter V; Duh MS; Fastenau J; Dirani R; Lefebvre P
Curr Med Res Opin; 2014 Aug; 30(8):1643-55. PubMed ID: 24730586
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Adjunctive Psychotropic Medications in Patients With Schizophrenia.
Stroup TS; Gerhard T; Crystal S; Huang C; Tan Z; Wall MM; Mathai C; Olfson M
JAMA Psychiatry; 2019 May; 76(5):508-515. PubMed ID: 30785609
[TBL] [Abstract][Full Text] [Related]
19. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
20. Time-to-therapy discontinuation in patients newly diagnosed with schizophrenia initiated on long-acting injectable versus oral dopamine receptor blocking agents.
Schwartz S; Lee S; Coble EB; Troxler C; Toscano S; Kumar A
Early Interv Psychiatry; 2023 Sep; 17(9):921-928. PubMed ID: 36639353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
